Since the CDK inhibitors THZ1 and dinaciclib were able to reduce TBXT expression in the model of an ultimately progressed chordoma (U-CH22), we next tested whether this might be an individual effect or whether additional models of progressed chordoma respond to these inhibitors as well. This evidence concerns the gene TBXT and chordoma.